ARTICLE | Product Development
As iTeos, GSK shelve belrestotug, prospects for TIGIT continue to dim
Immuno-oncology asset anchored $625M deal
May 14, 2025 1:38 AM UTC
A discontinuation by iTeos and GSK and the subsequent dissolution of the partners’ deal for the biotech’s lead asset are the latest developments in the rise and fall of immune checkpoint target TIGIT.
iTeos Therapeutics Inc. (NASDAQ:ITOS) announced Tuesday that the 10-year-old Watertown, Mass.-based company is dropping belrestotug (EOS-448), its anti-TIGIT mAb, after partner GSK plc (LSE:GSK; NYSE:GSK) determined it failed to meet expectations in two Phase II studies...